Crossmark

A Framework for Safety Evaluation Throughout the Product Development Life-Cycle

Crossref DOI link: https://doi.org/10.1007/s43441-019-00021-5

Published Online: 2019-12-09

Published Print: 2020-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ball, Greg

Reblin, Tjark

Buchanan, James

Hendrickson, Barbara A.

Lewis, Eric

Schnell, Patrick M.

Rockhold, Frank W.
License Information

Text and Data Mining valid from 2019-12-09
More Information

Article History

Received: 5 September 2019

Accepted: 18 November 2019

First Online: 9 December 2019

Compliance with Ethical Standards

:

: Dr. Schnell reports personal fees from Merck & Co, Inc, outside the submitted work. Dr. Rockhold reports grants from AstraZeneca, grants and personal fees from Janssen, personal fees from Merck Research Labs, personal fees from Merck Healthcare KGaA, personal fees from Novo Nordisk, personal fees from Rhythm, personal fees from KLSMC, personal fees from Aldeyra, personal fees from Complexa, personal fees from Sarepta, grants and personal fees from Eidos, grants from American Regent, grants from Reneuron, personal fees from Phathom, other from Athira, other from Spencer Healthcare, other from Datavant, grants from BMS, outside the submitted work.